Cargando…
Promising Drug Fondaparinux for the Treatment of COVID-19: an In Silico Analysis of Low Molecular Weight Heparin, Direct Oral Anticoagulant, and Antiplatelet Drug Interactions with Host Protease Furin
PURPOSE: As of July 2022, the COVID-19 pandemic has affected over 555 million worldwide confirmed cases and caused more than 6.3 million deaths. The studies showed that the D-dimer levels were increased in non-survivors compared to survivors and heparin treatment has begun to be administered to the...
Autores principales: | Ertan-Bolelli, Tugba, Bolelli, Kayhan, Elçi, Sıtkı Doga, Belen-Apak, F. Burcu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676724/ https://www.ncbi.nlm.nih.gov/pubmed/36401727 http://dx.doi.org/10.1007/s10557-022-07406-z |
Ejemplares similares
-
Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study
por: Bolelli, Kayhan, et al.
Publicado: (2021) -
The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018) -
Fondaparinux sodium/heparin: Type II heparin-induced thrombocytopenia and drug cross reactivity: case report
Publicado: (2022) -
Failure of Fondaparinux in Autoimmune Heparin-Induced Thrombocytopenia
por: Sartori, Michelangelo, et al.
Publicado: (2020) -
AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
por: Winzely, Maximilian, et al.
Publicado: (2021)